|
C14ORF135 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.21314069900791E-12 |
| Normal-vs-Stage2 |
7.18389999709856E-08 |
| Normal-vs-Stage3 |
3.03868041839905E-13 |
| Normal-vs-Stage4 |
1.71862524211974E-13 |
| Stage1-vs-Stage2 |
7.122600E-01 |
| Stage1-vs-Stage3 |
5.315500E-02 |
| Stage1-vs-Stage4 |
2.096700E-03 |
| Stage2-vs-Stage3 |
3.381600E-01 |
| Stage2-vs-Stage4 |
9.157900E-02 |
| Stage3-vs-Stage4 |
3.392000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.66133814775094E-16 |
| Normal-vs-AfricanAmerican |
3.774200E-04 |
| Normal-vs-Asian |
7.14240000032618E-07 |
| Caucasian-vs-AfricanAmerican |
1.837440E-01 |
| Caucasian-vs-Asian |
1.808990E-01 |
| AfricanAmerican-vs-Asian |
7.701800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.9393154576951E-12 |
| Normal-vs-Female |
1.75826020409886E-12 |
| Male-vs-Female |
4.152300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.65707505681712E-12 |
| Normal-vs-Age(41-60Yrs) |
2.13284945260739E-12 |
| Normal-vs-Age(61-80Yrs) |
1.68276503842435E-12 |
| Normal-vs-Age(81-100Yrs) |
7.759600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.180800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.709600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.326400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.090000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.658200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.173000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.096440E-01 |
| Classical-VS-Follicular |
1.275550E-01 |
| Classical-VS-Other |
6.121600E-01 |
| Classical-VS-Normal |
4.96509999781125E-09 |
| Tall-VS-Follicular |
7.181600E-01 |
| Tall-VS-Other |
7.542400E-01 |
| Tall-VS-Normal |
4.6347999993479E-08 |
| Follicular-VS-Other |
9.330000E-01 |
| Follicular-VS-Normal |
8.62000026913279E-10 |
| Other-VS-Normal |
4.378300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.91509088774001E-14 |
| Normal-vs-N1 |
2.66490052247548E-10 |
| N0-vs-N1 |
6.837000E-01 |
|
|
